GlassScriptPhysician profile
Maria Baldo
NPI 1902946288
$40,036.68
in general payments reported to CMS, 2019-2025
17 companies · $5,136 in 2025
The $5,136 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $173 · 2022: $2,690 · 2023: $22K · 2024: $10K · 2025: $5,136.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $27K · Travel and Lodging: $7,193 · Food and Beverage: $2,940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,041.00 |
| Travel and Lodging | $7,192.83 |
| Food and Beverage | $2,939.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38,637.96 | 2022-2025 | |
| Incyte Corporation | $396.16 | 2021-2025 | Jakafi, Niktimvo, Niktimvo |
| Novartis Pharmaceuticals Corporation | $310.15 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.11 | 2021-2025 | Iclusig |
| Servier Pharmaceuticals LLC | $98.50 | 2023-2025 | |
| Daiichi Sankyo INC. | $74.23 | 2021-2024 | Vanflyta |
| Biolinerx USA, INC. | $68.56 | 2024 | Aphexda |
| Rigel Pharmaceuticals, INC. | $44.27 | 2022 | |
| Sobi, INC | $35.84 | 2024-2025 | |
| Astellas Pharma US INC | $30.66 | 2025 | Cresemba |
| Azurity Pharmaceuticals, INC. | $26.56 | 2025 | Danziten |
| Blueprint Medicines Corporation | $26.04 | 2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $25.47 | 2025 | Ultomiris |
| Stemline Therapeutics INC. | $24.55 | 2025 | Elzonris |
| Morphosys, US INC. | $22.97 | 2023 | Monjuvi |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $22.08 | 2023 | |
| Pharmaessentia USA Corporation | $20.57 | 2023 | Besremi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Baldo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.